| 產(chǎn)品編號 | bs-5726R-Cy7 |
| 英文名稱 | Rabbit Anti-BubR1/Cy7 Conjugated antibody |
| 中文名稱 | Cy7標記的有絲分裂檢驗點蛋白BubR1抗體 |
| 別 名 | Beta homolg of S. cerevisiae BUB 1; Beta homolg of S. cerevisiae budding uninhibited by benzimidazoles; BUB 1B; BUB1 budding uninhibited by benzimidazoles 1 homolog beta; Bub1A; BUB1B; BUB1B_HUMAN; BUB1beta; BUBR1; Budding Uninhibited by Benzimidazoles 1 beta; hBUBR1; MAD3/BUB1 related protein kinase; MAD3/BUB1-related protein kinase; MAD3L; Mitotic checkpoint gene BUB1B; Mitotic checkpoint kinase MAD3L; Mitotic checkpoint serine/threonine protein kinase BUB1 beta; Mitotic checkpoint serine/threonine-protein kinase BUB1 beta; Protein SSK1; SSK 1; SSK1. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領(lǐng)域 | 腫瘤 細胞生物 免疫學 染色質(zhì)和核信號 細胞周期蛋白 激酶和磷酸酶 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | (predicted: Human, Mouse, Cow, Rabbit, ) |
| 產(chǎn)品應用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 120kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human BubR1 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: This gene encodes a kinase involved in spindle checkpoint function. The protein has been localized to the kinetochore and plays a role in the inhibition of the anaphase-promoting complex/cyclosome (APC/C), delaying the onset of anaphase and ensuring proper chromosome segregation. Impaired spindle checkpoint function has been found in many forms of cancer. [provided by RefSeq, Jul 2008] Function: Essential component of the mitotic checkpoint. Required for normal mitosis progression. The mitotic checkpoint delays anaphase until all chromosomes are properly attached to the mitotic spindle. One of its checkpoint functions is to inhibit the activity of the anaphase-promoting complex/cyclosome (APC/C) by blocking the binding of CDC20 to APC/C, independently of its kinase activity. The other is to monitor kinetochore activities that depend on the kinetochore motor CENPE. Required for kinetochore localization of CENPE. Negatively regulates PLK1 activity in interphase cells and suppresses centrosome amplification. Also implicated in triggering apoptosis in polyploid cells that exit aberrantly from mitotic arrest. May play a role for tumor suppression. Subunit: Interacts with CENPE, CENPF, mitosin, PLK1 and BUB3. Part of a complex containing BUB3, CDC20 and BUB1B. Interacts with anaphase-promoting complex/cyclosome (APC/C). Interacts with CASC5. Subcellular Location: Cytoplasm. Nucleus. Chromosome, centromere, kinetochore. Cytoplasm, cytoskeleton, centrosome. Tissue Specificity: Highly expressed in thymus followed by spleen. Preferentially expressed in tissues with a high mitotic index. Post-translational modifications: Proteolytically cleaved by caspase-3 in a cell cycle specific manner. The cleavage might be involved in the durability of the cell cycle delay. Caspase-3 cleavage is associated with abrogation of the mitotic checkpoint. The major site of cleavage is at Asp-610. Acetylation at Lys-250 regulates its degradation and timing in anaphase entry. Ubiquitinated. Degraded by the proteasome. Sumoylated with SUMO2 and SUMO3. The sumoylation mediates the association with CENPE at the kinetochore. Autophosphorylated in vitro. Intramolecular autophosphorylation is stimulated by CENPE. Phosphorylated during mitosis and hyperphosphorylated in mitotically arrested cells. Phosphorylation at Ser-670 and Ser-1043 occurs at kinetochores upon mitotic entry with dephosphorylation at the onset of anaphase. DISEASE: Note=Defects in BUB1B are associated with tumor formation. Premature chromatid separation trait (PCS) [MIM:176430]:Consists of separate and splayed chromatids with discerniblecentromeres and involves all or most chromosomes of a metaphase. Itis found in up to 2% of metaphases in cultured lymphocytes fromapproximately 40% of normal individuals. When PCS is present in 5%or more of cells, it is known as the heterozygous PCS trait and hasno obvious phenotypic effect, although some have reported decreasedfertility. Inheritance is autosomal dominant. Note=The disease iscaused by mutations affecting the gene represented in this entry. Mosaic variegated aneuploidy syndrome 1 (MVA1)[MIM:257300]: A severe developmental disorder characterized bymosaic aneuploidies, predominantly trisomies and monosomies,involving multiple different chromosomes and tissues. Affectedindividuals typically present with severe intrauterine growthretardation and microcephaly. Eye anomalies, mild dysmorphism,variable developmental delay, and a broad spectrum of additionalcongenital abnormalities and medical conditions may also occur. Therisk of malignancy is high, with rhabdomyosarcoma, Wilms tumor andleukemia reported in several cases. Note=The disease is caused bymutations affecting the gene represented in this entry. MVA1 iscaused by biallelic mutations in the BUB1B gene. Similarity: Belongs to the protein kinase superfamily. Ser/Thr protein kinase family. BUB1 subfamily. Contains 1 BUB1 N-terminal domain. Contains 1 protein kinase domain. Database links: Entrez Gene: 701 Human Omim: 602860 Human SwissProt: O60566 Human Unigene: 513645 Human Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. BubR1是存在于哺乳動物中的有絲分裂檢查點基因家族Mad3的同源基因,其編碼蛋白BubR1是一個多結(jié)構(gòu)域蛋白,在監(jiān)測細胞有絲分裂前中期向后期轉(zhuǎn)化的過程中扮演重要的角色。 |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
